Urology
Volume 72, Issue 6 , Pages 1298-1302, December 2008

A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer

  • Edouard J. Trabulsi

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
  • ,
  • Richard K. Valicenti

      Affiliations

    • Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Richard K. Valicenti, MD, Department of Radiation Oncology, Thomas Jefferson University, 111 S. 11th St, Philadelphia, PA 19107
  • ,
  • Alexandra L. Hanlon

      Affiliations

    • Department of Biostatistics, Temple University, Philadelphia, Pennsylvania
  • ,
  • Thomas M. Pisansky

      Affiliations

    • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
  • ,
  • Howard M. Sandler

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
  • ,
  • Deborah A. Kuban

      Affiliations

    • Department of Radiation Oncology, MD, Anderson Cancer Center, Houston, Texas
  • ,
  • Charles N. Catton

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
  • ,
  • Jeff M. Michalski

      Affiliations

    • Department of Radiation Oncology, Washington University, St. Louis, Missouri
  • ,
  • Michael J. Zelefsky

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
  • ,
  • Patrick A. Kupelian

      Affiliations

    • Department of Radiation Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • ,
  • Daniel W. Lin

      Affiliations

    • Department of Urology, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Mitchell S. Anscher

      Affiliations

    • Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina
  • ,
  • Kevin M. Slawin

      Affiliations

    • Department of Urology, Baylor College of Medicine, Houston, Texas
  • ,
  • Claus G. Roehrborn

      Affiliations

    • Department of Urology, University of Texas-Southwestern Medical Center, Dallas, Texas
  • ,
  • Jeffrey D. Forman

      Affiliations

    • Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, Michigan
  • ,
  • Stanley L. Liauw

      Affiliations

    • Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida
  • ,
  • Larry L. Kestin

      Affiliations

    • Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan
  • ,
  • Theodore L. DeWeese

      Affiliations

    • Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland
  • ,
  • Peter T. Scardino

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York
  • ,
  • Andrew J. Stephenson

      Affiliations

    • Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • ,
  • Alan Pollack

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Received 16 January 2008; accepted 13 May 2008. published online 30 July 2008.

Objectives

It is unclear whether postoperative salvage radiation therapy (SRT) and early adjuvant radiotherapy (ART) after radical prostatectomy lead to equivalent long-term tumor control. We studied a group of patients undergoing ART by comparing them with a matched control group undergoing SRT after biochemical failure.

Methods

Using a multi-institutional database of 2299 patients, 449 patients with pT3-4N0 disease were eligible for inclusion, including 211 patients receiving ART and 238 patients receiving SRT. Patients were matched in a 1:1 ratio according to preoperative prostate-specific antigen Gleason score, seminal vesicle invasion, surgical margin status, and follow-up from date of surgery.

Results

A total of 192 patients were matched (96:96). The median follow-up was 94 months from surgery and 73 months from RT completion. There was a significant reduction in biochemical failure with ART compared with SRT. The 5-year freedom from biochemical failure (FFBF) from surgery was 75% after ART, compared with 66% for SRT (hazard ratio [HR] = 1.6, P = .049). The 5-year FFBF from the end of RT was 73% after ART, compared with 50% after SRT (HR = 2.3, log rank [LR] P = .0007). From the end of RT, SRT and Gleason score ≥8 were independent predictors of diminished FFBF. From the date of surgery, Gleason score ≥8 was a significant predictor of FFBF.

Conclusions

Early ART for pT3-4N0 prostate cancer significantly reduces the risk of long-term biochemical progression after radical prostatectomy compared with SRT. Gleason score ≥8 was the only factor on multivariate analysis associated with metastasic progression.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0090-4295(08)00770-X

doi:10.1016/j.urology.2008.05.057

Refers to article:

  • Editorial Comment

    Mack Roach
    Urology December 2008 (Vol. 72, Issue 6, Pages 1302-1303)

  • Reply

    Edouard J. Trabulsi, Richard K. Valicenti
    Urology December 2008 (Vol. 72, Issue 6, Page 1303)

Urology
Volume 72, Issue 6 , Pages 1298-1302, December 2008